文献速递肺结节与肺癌

循环肿瘤DNA在非小细胞肺癌体细胞突变识别与肿瘤进化追踪中的价值

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
PubMed 文献 · Chest · 2021-04-18

该回顾性研究纳入370例非小细胞肺癌患者,评估循环肿瘤DNA(ctDNA)在突变识别、生存关联、与组织样本一致性及肿瘤进化监测中的价值。结果显示ctDNA与组织活检效用相似,但组织活检遗漏了更多可靶向基因突变,提示ctDNA联合组织活检可能有助于发现额外可靶向突变。

要点

  • ctDNA与组织活检在突变检测上效用相似,但组织活检遗漏更多可靶向突变。
  • 低累积ctDNA水平与更长的无进展生存期相关(HR 0.56)。
  • BRAF、PIK3CA和KRAS突变与更短的总生存期相关。

核心结论

  • ctDNA分析与组织活检效用相似,但组织活检遗漏更多可靶向基因突变,ctDNA联合组织活检可能改善晚期NSCLC临床结局。

主要发现

  • 在370例患者的473份ctDNA样本中检测到1688个体细胞突变,其中177份样本显示至少一个可用FDA批准NSCLC疗法的可操作突变。
  • 基因水平一致性为93.8%,阳性一致率为41.6%;ctDNA中发现的靶向基因突变多于组织活检。
  • 重复ctDNA样本可检测治疗反应和肿瘤进化。

关键数值与推荐

  • MET和CDK6扩增与BRAF扩增共现(FDR<0.01),KRAS与EGFR基因水平突变互斥(FDR=0.0009)。

临床怎么用

  • 在晚期NSCLC中,ctDNA评估可联合组织活检以发现额外可靶向突变,并可用于监测治疗反应和肿瘤进化。

局限性

  • 回顾性研究设计,单中心数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The usefulness of circulating tumor DNA (ctDNA) in detecting mutations and monitoring treatment response has not been well studied beyond a few actionable biomarkers in non-small cell lung cancer (NSCLC). RESEARCH QUESTION: How does the usefulness of ctDNA analysis compare with that of solid tumor biopsy analysis in patients with NSCLC? METHODS: We retrospectively evaluated 370 adult patients with NSCLC treated at the City of Hope between November 2015 and August 2019 to assess the usefulness of ctDNA in mutation identification, survival, concordance with matched tissue samples in 32 genes, and tumor evolution. RESULTS: A total of 1,688 somatic mutations were detected in 473 ctDNA samples from 370 patients with NSCLC. Of the 473 samples, 177 showed at least one actionable mutation with currently available Food and Drug Administration-approved NSCLC therapies. MET and CDK6 amplifications co-occurred with BRAF amplifications (false discovery rate [FDR], < 0.01), and gene-level mutations were mutually exclusive in KRAS and EGFR (FDR, 0.0009). Low cumulative percent ctDNA levels were associated with longer progression-free survival (hazard ratio [HR], 0.56; 95% CI, 0.37-0.85; P = .006). Overall survival was shorter in patients harboring BRAF mutations (HR, 2.35; 95% CI, 1.24-4.6; P = .009), PIK3CA mutations (HR, 2.77; 95% CI, 1.56-4.9; P < .001) and KRAS mutations (HR, 2.32; 95% CI, 1.30-4.1; P = .004). Gene-level concordance was 93.8%, whereas the positive concordance rate was 41.6%. More mutations in targetable genes were found in ctDNA than in tissue biopsy samples. Treatment response and tumor evolution over time were detected in repeated ctDNA samples. INTERPRETATION: Although ctDNA analysis exhibited similar usefulness to tissue biopsy analysis, more mutations in targetable genes were missed in tissue biopsy analyses. Therefore, the evaluation of ctDNA in conjunction with tissue biopsy samples may help to detect additional targetable mutations to improve clinical outcomes in advanced NSCLC.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Roosan MR, Mambetsariev I, Pharaon R, et al. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest. 2021. PMID: 33878340. doi:10.1016/j.chest.2021.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。